DUBLIN, May 23, 2017 /PRNewswire/ -- Allergan plc, (NYSE:
AGN), a leading global pharmaceutical company, announced that
Emmy® and Tony® award-winning actress and
singer, Kristin Chenoweth will kick
off the "Less Red, More You" campaign today at an exclusive event
in New York City. As part of the
campaign, Ms. Chenoweth, who suffers from rosacea, will ignite a
nationwide conversation about the typically underserved condition
while raising awareness for RHOFADE™ cream, a new product indicated
for the topical treatment of persistent facial erythema associated
with rosacea in adults.1
"As a performer who is constantly on stage or in front of the
camera, it's important that I take care of my skin, but
unfortunately, persistent facial redness from rosacea is something
I've struggled with every day for years," said Chenoweth. "I've
been searching for a product that, with daily use, can help keep my
redness in check. Recently, my dermatologist recommended something
new. She gave me RHOFADE™ cream, a treatment I use once-a-day,
every day that helps reduce my redness all-day, through 12 hours so
I see less red and more me.1 I'm thrilled to partner
with Allergan to raise awareness for the persistent facial redness
people with rosacea may deal with and RHOFADE™ cream. I hope that
my experience can help make a difference for other sufferers who
deal with this challenging condition every day."
"Kristin is the perfect partner to help us increase awareness
about this condition as she understands the daily challenges of
living with rosacea," said Jag Dosanjh, Senior Vice-President of
Medical Dermatology at Allergan. "She is among the 16 million
Americans who have rosacea, yet we know only a small fraction of
that number is actually receiving treatment. Persistent facial
redness is the most common sign of rosacea and is bothersome for
patients, and now, RHOFADE™ cream can help patients take a
step closer to achieving a more normal, healthy skin color."1,
2,3
In two clinical trials, once-daily application of RHOFADE™ cream
was proven to reduce persistent facial erythema associated
with rosacea through 12 hours on day 29. Results seen in
12%–18% of people using RHOFADE™ cream vs 5%–9% of people using
vehicle cream. The most common adverse reactions for
RHOFADE™ were application site dermatitis,
worsening inflammatory lesions of rosacea, application site
pruritus, application site erythema, and application site
pain.1
Patients who experience persistent facial redness should talk to
their dermatologist about their condition. RHOFADE™ is currently
available with a prescription. For more information, visit
www.Rhofade.com.
INDICATION
RHOFADE™ (oxymetazoline hydrochloride) Cream
1% is indicated for the topical treatment of persistent facial
erythema associated with rosacea in adults.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Potential Impacts on
Cardiovascular Disease
Alpha-adrenergic agonists may impact
blood pressure. RHOFADE™ should be
used with caution in patients with severe or unstable or
uncontrolled cardiovascular disease, orthostatic hypotension,
and/or uncontrolled hypertension/hypotension. Advise patients with
cardiovascular disease, orthostatic hypotension, and/or
uncontrolled hypertension/hypotension to seek immediate medical
care if their condition worsens.
Potentiation of Vascular Insufficiency
RHOFADE™ should be used with caution
in patients with cerebral or coronary insufficiency, Raynaud's
phenomenon, thromboangiitis obliterans, scleroderma, or Sjögren's
syndrome. Advise patients to seek immediate medical care if
signs and symptoms of potentiation of vascular insufficiency
develop.
Risk of Angle Closure Glaucoma
RHOFADE™ may increase the risk of angle
closure glaucoma in patients with narrow-angle glaucoma. Advise
patients to seek immediate medical care if signs and symptoms of
acute angle closure glaucoma develop.
ADVERSE REACTIONS
The most common adverse reactions for RHOFADETM were:
application site dermatitis 2 %, worsening inflammatory lesions of
rosacea 1%, application site pruritus 1%, application site erythema
1%, and application site pain 1%.
Please see RHOFADE™ full
Prescribing Information.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceutical, device,
biologic, surgical and regenerative medicine products for patients
around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of
research and development, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. With this approach, Allergan has built one of the
broadest development pipelines in the pharmaceutical industry with
70+ mid-to-late stage pipeline programs currently in
development.
Allergan's success is powered by our more than 18,000 global
colleagues' commitment to being Bold for Life. Together, we build
bridges, power ideas, act fast and drive results for our customers
and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2016 and Allergan's Quarterly Report on Form 10-Q for the
period ended March 31, 2017. Except
as expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
References:
1. RHOFADE™ Prescribing Information, 2017.
2. National Rosacea Society, If You Have Rosacea, You're
Not Alone, Nationals Rosacea Society website,
https://www.rosacea.org/patients/index.php. Accessed March 1, 2017.
3. National Rosacea Society, All About Rosacea. National
Rosacea Society website,
https://www.rosacea.org/patients/allaboutrosacea.php. Accessed
March 1, 2017.
© 2017 Allergan. All rights reserved. All trademarks are the
property of their respective owners.
CONTACTS:
Investors:
Daphne
Karydas
(862) 261-8006
Media:
Mark Marmur
(862) 261-7558
Ember Garrett
(714) 246-3525
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/kristin-chenoweth-kicks-off-less-red-more-you-campaign-to-launch-rhofade-oxymetazoline-hcl-cream-1-300461896.html
SOURCE Allergan plc